Busulfan, cyclophosphamide, imatinib mesylate and autologous stem cell transplantation in patients with chronic myelogenous leukaemia.

Trial Profile

Busulfan, cyclophosphamide, imatinib mesylate and autologous stem cell transplantation in patients with chronic myelogenous leukaemia.

Completed
Phase of Trial: Phase II

Latest Information Update: 31 Oct 2011

At a glance

  • Drugs Imatinib (Primary) ; Busulfan; Cyclophosphamide
  • Indications Chronic myeloid leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 29 Oct 2009 Actual end date (Oct 2009) added as reported by ClinicalTrials.gov.
    • 29 Oct 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 18 Jan 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top